08/31/2017

IDSA Comments to Interagency Coordination Group on Antimicrobial Resistance (PDF)

IDSA comments to the Ad-hoc Interagency Coordination Group (ICG) on Antimicrobial Resistance (AMR) summarizing IDSA recommendations to implement the United Nations General Assembly (UNGA) Political Declaration and Global Action Plan (GAP) on AMR and highlighting opportunities for IDSA-ICG collaboration.

02/01/2017

IDSA Support for UN General Assembly Declaration on Antimicrobial Resistance (PDF)

IDSA expressed strong support for the political declaration that resulted from the UN General Assembly high level meeting on antimicrobial resistance in September 2016, and urges UN and WHO leaders to move quickly to implement the strategies outlined in the political declaration.

01/13/2017

IDSA Leads Health Groups in Letter to New Administration Urging Continuation of AMR Efforts (PDF)

IDSA coordinated a letter, joined by 47 other health groups, to President-elect Trump urging that federal efforts to combat antimicrobial resistance be maintained in the years ahead.

11/28/2016

IDSA Outlines ID Policy Issues for Trump Transition Team (PDF)

IDSA outlines important ID policy issues for Vice President-elect Mike Pence, head of the Trump Transition Team.

10/04/2016

IDSA Letter to WHO on Prioritizing Antimicrobial Resistant Pathogens (PDF)

IDSA reached out to World Health Organization Director Dr. Margaret Chan on the need to prioritize antimicrobial resistant pathogens as it develops its Global R&D Priority Pathogens List.

07/07/2016

IDSA Recommendations to United Nations on Antimicrobial Resistance (PDF)

IDSA provided recommendations in advance of a United Nations (UN) High Level Meeting on Antimicrobial Resistance in September; IDSA recommends focus on surveillance data collection, antimicrobial stewardship, antimicrobial drug and diagnostic research and development, vaccination and infection prevention, and investment in an infectious diseases physician workforce.

03/21/2016

IDSA Comments to PACCARB (PDF)

IDSA presented comments at a public meeting of the Presidential Advisory Council on Antibiotic-Resistant Bacteria (PACCARB). IDSA applauded the PACCARB for its work so far on the five goals of the National Action Plan for Combating Antibiotic Resistant Bacteria, and highlighted specific recommendations to advance each of the goals in the National Action Plan.

05/15/2015

IDSA Statement on 21st Century Cures Vote by House Energy and Commerce Subcommittee on Health (PDF)

IDSA applauds the Health Subcommittee of the House Energy and Commerce Committee for to advance key provisions in the 21st Century Cures Initiative to promote urgently needed antibiotic research and development (R&D), boost funding for the National Institutes of Health (NIH), support young emerging scientists, and support innovative biomedical research.

09/19/2014

IDSA President Provides Testimony on the Need for New Antibiotics (PDF)

On September 19, IDSA President Barbara Murray provided testimony to the Health Subcommittee of the House Energy & Commerce Committee on the need for a coordinated federal strategy to spur research and development for new antibiotics. The hearing was convened as part of the Committee's 21st Century Cures Initiative.

04/04/2014

IDSA Statement at PCAST Public Meeting on Antibiotic Resistance (PDF)

IDSA presented comments at the President's Council of Advisors on Science and Technology (PCAST) Public Meeting on Antibiotic Resistance. IDSA is encouraged by the closer attention the federal government is paying to the public health crisis posed by antibiotic resistance, but the need for comprehensive, concrete actions is overdue.

09/16/2013

Antibiotic Resistance Threats in the United States, 2013

CDC report providing a detailed snapshot of the burdens and threats posed by the antibiotic-resistant germs having the most impact on human health.

04/17/2013

10 × '20 Progress—Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America

The current report updates the status of development and approval of systemic antibiotics for Gram negative bacteria in the United States, as part of The 10 x ’20 Initiative.

03/01/2013

IDSA Statement on Limited Population Antibacterial Drug (LPAD) Approval Mechanism (PDF)

The Society submits comments to the Food and Drug Administration (FDA) on LPAD in response to the Agency's Part 15 hearing.

03/08/2012

IDSA Congressional Testimony on Antibiotic R&D and 2012 PDUFA Legislation (PDF)

In testimony to Congress, IDSA proposed a new approval pathway for anti-infective therapies for serious resistant infections where few treatments are available.

12/13/2011

IDSA Statement for Senate Committee Hearing on Drug Shortages (PDF)

IDSA provided a statement for the record for the Senate Health, Education, Labor and Pensions Committee hearing on drug shortages. IDSA highlighted the serious anti-infective shortages and their impact on patient care and public health, and offered strategies to address this problem.

04/07/2011

Combating Antimicrobial Resistance: Policy Recommendations to Save Lives

Infectious Diseases Society of America, Clinical Infectious Diseases vol. 52 supp. 5 7 April 2011 397-428.

02/22/2011

Preserving the Lifesaving Power of Antimicrobial Agents

Hughes, The Journal of the American Medical Association vol. 305 no. February 22, 2011 1027-1028.

A commentary in JAMA by IDSA President James Hughes, MD, FIDSA (subscription required).

09/29/2010

IDSA Testimony on Medical Countermeasures Enterprise Review (PDF)

Dr. Andy Pavia testified on behalf of IDSA at a September 29, 2010 hearing of the Senate Labor-Health and Human Services-Education Appropriations Subcommittee examining the Public Health Emergency Medical Countermeasures Enterprise review completed by the Department of Health and Human Services in August 2010.

06/09/2010

IDSA Testimony on Antibiotic Resistance, delivered before the House Energy and Commerce Health Subcommittee (PDF)

Brad Spellberg, MD, FIDSA, presented IDSA's statement at a hearing on “Promoting the Development of Antibiotics and Ensuring Judicious Use in Humans.”

04/15/2010

The 10 x ’20 Initiative Inaugural Statement

IDSA, Clinical Infectious Diseases vol. 50 no. 8 April 15, 2010 1081-1083.

IDSA and other organizations call for a global commitment to develop 10 new systemic antibiotics by 2020.

11/20/2009

New US/EU Transatlantic Task Force on Antimicrobial Resistance and IDSA's 10x'20 Initiative

Robert Guidos, JD, IDSA VP, Public Policy & Government Relations, outlines IDSA's position in an invited guest column of the Center for Global Development's newsletter.

01/01/2009

Bad Bugs, No Drugs, No ESKAPE: An Update on the State of the Pipeline (PDF)

Boucher et al., Clinical Infectious Diseases vol. 48 no. 1 January 1, 2009

IDSA expresses concern about the lean pipeline for novel therapeutics to treat drug-resistant infections, especially those caused by gram-negative pathogens.

01/15/2008

The Epidemic of Antimicrobial Resistant Infections (PDF)

Spellberg et al., Clinical Infectious Diseases vol. 46 no. 2 January 15, 2008 155-164.

A call to action for the medical community from the Infectious Diseases Society of America.

04/06/2006

Project Bioshield Reauthorization (PDF)

A statement from Martin J. Blaser, MD, IDSA's President.

03/01/2006

Bad Bugs Need Drugs: An Update on the Development Pipeline (PDF)

Talbot et al., Clinical Infectious Diseases vol. 42 no. 5 March 1, 2006.

An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.

07/01/2004

Bad Bugs, No Drugs: As Antibiotic Discovery Stagnates, A Public Health Crisis Brews (PDF)

IDSA called for statutory incentives and other interventions to address the lack of new antibiotics to fight drug-resistant bacterial infections.

View all statements for 10 x '20 Initiative

Infectious Diseases Society of America